



Antibodies in Influenza Vaccine and Therapeutic Design

Guest Editor:

Dr. Hillary Anne Vanderven

College of Public Health, Medical
& Vet Sciences, James Cook
University, Douglas, QLD 4811,
Australia

Deadline for manuscript
submissions:

closed (10 June 2021)

Message from the Guest Editor

Dear Colleagues,

A universal influenza vaccine that provides broad protection has eluded influenza virus researchers for decades. The effectiveness of current influenza vaccines is limited by antigenic drift, antigenic shift and suboptimal responses in high-risk groups. To overcome these issues, there has been a renewed interest in developing influenza vaccines that induce broadly-reactive antibodies targeting conserved regions of the influenza virus (such as the hemagglutinin stem). Passive infusions of monoclonal or polyclonal antibodies have also demonstrated promising results as a potential therapeutic intervention for severe influenza infections. As such, antibodies are central to the development of more universal influenza vaccines and novel anti-viral therapies. In this Special Issue, we invite you to submit research articles and reviews on a range of research topics relating to the role of Antibodies in Influenza Vaccine and Therapeutic Design.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com